Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease.
Saved in:
| Title: | Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease. |
|---|---|
| Authors: | Di Caro V; Cognition Therapeutics, 2403 Sidney Street Suite 261, Pittsburgh, 15203, PA, USA., Cho E; Cognition Therapeutics, 2403 Sidney Street Suite 261, Pittsburgh, 15203, PA, USA., Thiel J; Cognition Therapeutics, 2403 Sidney Street Suite 261, Pittsburgh, 15203, PA, USA., Lizama BN; Cognition Therapeutics, 2403 Sidney Street Suite 261, Pittsburgh, 15203, PA, USA., Koel-Simmelink MJA; Department of Laboratory Medicine, VU University Medical Center, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands., Pandey K; Emtherapro Inc, Systems Biology, 1374 Pasadena Avenue NE, Atlanta, GA, 30306, USA., Duong D; Emory University School of Medicine, Biochemistry, 1510 Clifton Road, 4001 Rollins Research Center, Atlanta, GA, 30322, USA., Seyfried NT; Emory University School of Medicine, Biochemistry, 1510 Clifton Road, 4001 Rollins Research Center, Atlanta, GA, 30322, USA., Grundman M; Global R&D Partners, LLC, 13236 Haxton Place, San Diego, CA, 92130, USA.; Department of Neurosciences, University of California, 9375 Gilman Dr, San Diego, CA, 92161, USA., Teunissen CE; Department of Laboratory Medicine, VU University Medical Center, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.; UK Dementia Research Institute at UCL, London, UK.; Hong Kong Center for Neurodegenerative Diseases, InnoHK, Hong Kong, China.; Centre for Brain Research, Indian Institute of Science, Bangalore, India., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Caggiano AO; Cognition Therapeutics, 2403 Sidney Street Suite 261, Pittsburgh, 15203, PA, USA., Hamby ME; Cognition Therapeutics, 2403 Sidney Street Suite 261, Pittsburgh, 15203, PA, USA. mhamby@cogrx.com. |
| Source: | Alzheimer's research & therapy [Alzheimers Res Ther] 2026 Apr 06; Vol. 18 (1). Date of Electronic Publication: 2026 Apr 06. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
